Steroid hormone

Steroid hormone signaling represents a fundamentally distinct mode of intercellular communication, characterized by the use of lipophilic molecules derived from cholesterol that exert profound effects on gene expression, development, metabolism, and homeostasis. Unlike the rapid, point-to-point transmission of neuronal signaling or the self-targeted nature of autocrine loops, steroid hormones are synthesized in specialized endocrine glands—such as the adrenal cortex, gonads, and placenta—and are released into the circulation for systemic (endocrine) delivery to distant target tissues (Miller & Auchus, 2011). Their lipophilic nature enables them to readily cross plasma membranes, a property that fundamentally shapes their mechanisms of action and distinguishes them from peptide and amine hormones that act via cell-surface receptors.

The biosynthesis of steroid hormones begins with the conversion of cholesterol to pregnenolone, a rate-limiting step catalyzed by the cholesterol side-chain cleavage enzyme (CYP11A1) located in the inner mitochondrial membrane (Payne & Hales, 2004). Subsequent tissue-specific enzymatic reactions produce the five major classes of steroid hormones: glucocorticoids (cortisol), mineralocorticoids (aldosterone), androgens (testosterone), estrogens (estradiol), and progestogens (progesterone) (Miller & Auchus, 2011). Once secreted, the majority of steroid hormones circulate bound to high-affinity carrier proteins, such as corticosteroid-binding globulin (CBG) and sex hormone-binding globulin (SHBG), which extend their half-lives and regulate their bioavailability (Hammond, 2016). The free, unbound fraction is thought to be biologically active and capable of diffusing through the lipid bilayer of target cell membranes.

The classical or genomic pathway of steroid hormone action involves binding to intracellular receptors that function as ligand-activated transcription factors. These receptors belong to the nuclear receptor superfamily and include the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), androgen receptor (AR), estrogen receptors (ERα and ERβ), and progesterone receptor (PR) (Mangelsdorf et al., 1995). In the absence of ligand, these receptors are typically sequestered in the cytoplasm by chaperone proteins, including heat shock protein 90 (Hsp90) and immunophilins, which maintain the receptor in a conformation competent for ligand binding (Pratt & Toft, 1997). Upon hormone binding, the receptor undergoes a conformational change, dissociates from the chaperone complex, and translocates to the nucleus, where it homodimerizes and binds to specific DNA sequences known as hormone response elements (HREs) located in the promoter or enhancer regions of target genes (Beato et al., 1995). This binding recruits coactivator or corepressor complexes that modify chromatin structure through histone acetylation or deacetylation, ultimately leading to the activation or repression of gene transcription (Rosenfeld et al., 2006). The genomic pathway is characterized by a lag time of minutes to hours, reflecting the time required for transcription and protein synthesis, and its effects are typically long-lasting, persisting for hours to days.

In addition to the classical genomic pathway, steroid hormones also elicit rapid, non-genomic effects that occur within seconds to minutes and are independent of transcriptional regulation. These rapid responses are mediated by receptors localized at or near the plasma membrane, which are either classical nuclear receptors that have been trafficked to the membrane or distinct membrane-associated receptors, such as G protein-coupled estrogen receptor 1 (GPER1) (Revelli et al., 1998; Prossnitz & Barton, 2011). Membrane-associated steroid receptors can activate intracellular signaling cascades, including the MAPK/ERK, PI3K/Akt, and cAMP/PKA pathways, leading to acute effects such as changes in ion channel activity, calcium mobilization, and nitric oxide synthesis (Lösel & Wehling, 2003). For instance, aldosterone rapidly activates the PKC pathway and sodium-hydrogen exchanger activity in vascular smooth muscle cells, while estradiol can rapidly stimulate endothelial nitric oxide synthase (eNOS) in the vascular endothelium, contributing to vasodilation (Levin, 2011). This integration of genomic and non-genomic actions allows steroid hormones to exert both sustained, adaptive changes in cellular phenotype and acute, homeostatic responses.

Steroid hormone signaling is also subject to complex regulatory mechanisms that confer tissue specificity and signal amplification. The 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, for example, interconvert active cortisol and inactive cortisone in target tissues, thereby modulating local glucocorticoid availability and conferring specificity upon the non-selective mineralocorticoid receptor (Funder et al., 1988; Seckl & Walker, 2001). Similarly, the enzyme aromatase converts androgens to estrogens, enabling local estrogen synthesis in tissues such as adipose, brain, and breast (Simpson et al., 2002). Receptor isoforms and splice variants, such as ERα and ERβ or the various GR isoforms, further expand the repertoire of hormonal responses, and coactivator and corepressor proteins are expressed in a cell-specific manner, allowing the same hormone to produce different transcriptional outcomes in different tissues (Klinge, 2001; Oakley & Cidlowski, 2013).

From a pathophysiological perspective, dysregulated steroid hormone signaling underlies a wide array of diseases. Glucocorticoid resistance or hypersensitivity are implicated in autoimmune disorders, metabolic syndrome, and major depression (Pariante, 2006). Estrogen signaling drives the majority of breast cancers, and endocrine therapies targeting the estrogen receptor (e.g., tamoxifen) or inhibiting estrogen synthesis (e.g., aromatase inhibitors) are mainstays of treatment (Cuzick et al., 2014). Androgen receptor signaling is central to prostate cancer progression, and androgen deprivation therapy and second-generation anti-androgens (e.g., enzalutamide) are widely employed (Shoag & Barbieri, 2016). Primary aldosteronism is a common cause of secondary hypertension, while congenital adrenal hyperplasia results from enzymatic defects in cortisol biosynthesis (Miller & Auchus, 2011). Moreover, mutations in the nuclear receptor itself or its coregulators contribute to endocrine resistance in cancers, necessitating the development of novel degraders and selective modulators.

References

Beato, M., Herrlich, P., & Schütz, G. (1995). Steroid hormone receptors: Many actors in search of a plot. Cell, 83(6), 851–857.

Cuzick, J., Sestak, I., & Forbes, J. F. (2014). Use of anastrozole for breast cancer prevention. The Lancet Oncology, 15(8), 788–789.

Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988). Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science, 242(4878), 583–585.

Hammond, G. L. (2016). Plasma steroid-binding proteins: Primary gatekeepers of steroid hormone action. Journal of Endocrinology, 230(1), R13–R25.

Klinge, C. M. (2001). Estrogen receptor interaction with co-activators and co-repressors. Steroids, 66(3-5), 211–223.

Levin, E. R. (2011). Minireview: Extranuclear steroid receptors: Roles in modulation of cell functions. Molecular Endocrinology, 25(3), 377–384.

Lösel, R., & Wehling, M. (2003). Nongenomic actions of steroid hormones. Nature Reviews Molecular Cell Biology, 4(1), 46–56.

Mangelsdorf, D. J., Thummel, C., Beato, M., et al. (1995). The nuclear receptor superfamily: The second decade. Cell, 83(6), 835–839.

Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews, 32(1), 81–151.

Oakley, R. H., & Cidlowski, J. A. (2013). The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease. Journal of Allergy and Clinical Immunology, 132(5), 1033–1044.

Pariante, C. M. (2006). The glucocorticoid receptor: A new target for antidepressant drugs? Journal of Psychopharmacology, 20(4 Suppl), 21–30.

Payne, A. H., & Hales, D. B. (2004). Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocrine Reviews, 25(6), 947–970.

Pratt, W. B., & Toft, D. O. (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews, 18(3), 306–360.

Prossnitz, E. R., & Barton, M. (2011). The G-protein-coupled estrogen receptor GPER in health and disease. Nature Reviews Endocrinology, 7(12), 715–726.

Revelli, A., Massobrio, M., & Tesarik, J. (1998). Nongenomic actions of steroid hormones in reproductive tissues. Endocrine Reviews, 19(1), 3–17.

Rosenfeld, M. G., Lunyak, V. V., & Glass, C. K. (2006). Sensors and signals: A coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes & Development, 20(11), 1405–1428.

Seckl, J. R., & Walker, B. R. (2001). Minireview: 11β-Hydroxysteroid dehydrogenase type 1—A tissue-specific amplifier of glucocorticoid action. Endocrinology, 142(4), 1371–1376.

Shoag, J., & Barbieri, C. E. (2016). Clinical variability and molecular heterogeneity in prostate cancer. Asian Journal of Andrology, 18(4), 543–548.

Simpson, E. R., Clyne, C., Rubin, G., et al. (2002). Aromatase—A brief overview. Annual Review of Physiology, 64, 93–127.